CD4 and neoplasm: Another biomarker that may predict response to ICIs in breast cancer is the presence of tumor infiltrating lymphocytes (TILs), such as CD4+ T cells, CD8+ T cells, NK cells, and Th1, which cause an anti-tumor effect through IFN-γ signaling [16, 17].